失代偿期肝硬化患者临床试验的终点与设计:LiverHope联盟立场文件
失代偿期肝硬化目前缺乏阻止疾病进展和预防并发症的疾病修饰疗法,其临床试验设计因人群异质性和终点不统一而复杂。LiverHope联盟召开专家会议,针对旨在改变自然病史、预防进展以及处理各并发症的试验,提出设计建议并定义合适的终点。
要点
- 失代偿期肝硬化患者人群异质(病因、合并症、疾病严重程度不同),试验纳入人群多样。
- 既往试验主要终点不统一,有时不适当,导致不同试验结果难以比较。
- 联盟建议针对改变自然病史与处理并发症两类试验分别定义终点和设计。
核心结论
- 失代偿期肝硬化目前尚无阻止疾病进展和预防并发症的疾病修饰疗法,管理仍以并发症发生后的治疗为主。
- LiverHope联盟通过专家会议提出针对失代偿期肝硬化临床试验设计和终点定义的建议。
研究设计与样本
- LiverHope联盟组织的专家会议,形成立场文件,制定临床试验设计建议并定义合适终点。
主要发现
- 失代偿期肝硬化人群异质(病因、合并症和疾病严重程度不同),导致临床试验纳入人群多样。
- 针对失代偿期肝硬化患者的试验主要终点不统一,有时可能不适当,造成不同试验结果难以比较。
关键数值与推荐
- 建议针对旨在改变自然病史和预防失代偿期肝硬化进展的试验定义合适终点。
- 建议针对旨在处理肝硬化各并发症的试验定义合适终点。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.
引用
- Solà E, Pose E, Campion D, et al. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol. 2020. PMID: 32896580. doi:10.1016/j.jhep.2020.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。